$103 Million is the total value of Stonepine Capital Management, LLC's 26 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 52.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | Buy | AMARIN CORP PLC -ADRspons adr new | $18,792,000 | +4.1% | 1,239,568 | +33.2% | 18.24% | +46.8% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $11,339,000 | +261.6% | 681,812 | +199.2% | 11.00% | +409.7% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $10,929,000 | -15.0% | 2,595,855 | -6.1% | 10.61% | +19.8% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $7,802,000 | +41.2% | 129,867 | +98.3% | 7.57% | +99.0% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $6,663,000 | +3.9% | 4,502,301 | -9.4% | 6.47% | +46.5% |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $5,102,000 | -8.1% | 860,449 | -1.3% | 4.95% | +29.5% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $4,814,000 | -42.6% | 1,463,188 | -43.3% | 4.67% | -19.1% |
| OPNT | Sell | OPIANT PHARMACEUTICALS INC | $4,727,000 | +13.1% | 314,073 | -0.4% | 4.59% | +59.4% |
| XOMA | Sell | XOMA CORP | $4,537,000 | +12.9% | 230,201 | -14.9% | 4.40% | +59.1% |
| ISEE | Sell | IVERIC BIO INC | $4,285,000 | -19.9% | 3,825,903 | -7.0% | 4.16% | +13.0% |
| HTGM | Buy | HTG MOLECULAR DIAGNOSTICS | $3,848,000 | -16.8% | 5,790,269 | +107.9% | 3.74% | +17.3% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $3,841,000 | -56.5% | 751,012 | -47.2% | 3.73% | -38.7% |
| CTIC | Sell | CTI BIOPHARMA CORP | $3,107,000 | -7.4% | 3,711,999 | -4.9% | 3.02% | +30.6% |
| LGND | Sell | LIGAND PHARMACEUTICALS | $2,983,000 | -84.4% | 29,965 | -82.1% | 2.90% | -78.0% |
| NVLNF | Buy | NOVELION THERAPEUTICS INC | $2,685,000 | +601.0% | 3,703,420 | +654.1% | 2.61% | +887.1% |
| APVO | Sell | APTEVO THERAPEUTICS INC | $2,008,000 | -42.3% | 3,413,421 | -13.0% | 1.95% | -18.6% |
| ALIM | Sell | ALIMERA SCIENCES INC | $1,552,000 | -72.9% | 2,740,417 | -57.4% | 1.51% | -61.8% |
| CORV | New | CORREVIO PHARMA CORP | $1,019,000 | – | 509,356 | +100.0% | 0.99% | – |
| IDXG | Sell | INTERPACE DIAGNOSTICS GROUP | $922,000 | -27.5% | 1,160,378 | -33.8% | 0.90% | +2.3% |
| CHMA | New | CHIASMA INC | $543,000 | – | 109,743 | +100.0% | 0.53% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $383,000 | – | 33,033 | +100.0% | 0.37% | – |
| ACER | New | ACER THERAPEUTICS INC | $364,000 | – | 114,175 | +100.0% | 0.35% | – |
| RTRX | New | RETROPHIN INC | $344,000 | – | 29,675 | +100.0% | 0.33% | – |
| AFMD | Sell | AFFIMED NV | $231,000 | -88.8% | 78,500 | -89.0% | 0.22% | -84.2% |
| DRRX | New | DURECT CORPORATION | $184,000 | – | 100,000 | +100.0% | 0.18% | – |
| DMAC | New | DIAMEDICA THERAPEUTICS INC | $28,000 | – | 13,705 | +100.0% | 0.03% | – |
| MOTS | Exit | MOTUS GI HOLDINGS INC | $0 | – | -35,205 | -100.0% | -0.07% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -162,244 | -100.0% | -0.35% | – |
| MTNB | Exit | MATINAS BIOPHARMA HOLDINGS I | $0 | – | -668,615 | -100.0% | -0.40% | – |
| VIVE | Exit | VIVEVE MEDICAL INC | $0 | – | -3,403,402 | -100.0% | -0.89% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -651,211 | -100.0% | -1.07% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -1,341,943 | -100.0% | -13.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.